- AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type of.
- AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type ofWe have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: